HeartSciences Inc. is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. The Company has libraries of artificial intelligence-enhanced electrocardiography (AI-ECG) algorithms and is developing AI-ECG solutions to be made available on either a hardware- agnostic cloud-based platform or its proprietary MyoVista wavECG device, to help identify cardiovascular disease in any care setting worldwide in a manner to suit different care providers. Its first product candidate for FDA clearance, the MyoVista wavECG, or the MyoVista, is a resting 12-lead ECG that is also designed to provide diagnostic information related to cardiac dysfunction, which has traditionally only been available through the use of cardiac imaging. The MyoVista also provides conventional ECG information in the same test. It delivers AI-ECG algorithms using existing ECG devices across a hospital or health system.
成長中
同社は成長フェーズにあり、最新の年間収益はUSD 4.32Kに達しています。
高い利益成長
同社の純利益は業界をリードしており、最新の年間純利益はUSD 4.32Kです。
割安
同社の最新のPEは-0.49で、過去3年間の水準と比較して安値圏にあります。
機関投資家の売り越し
最新の機関投資家の保有株数は198.36K株で、前四半期比で10.34%減少しています。
市場活動が低調
同社への投資家の関心は低下しており、20日間の売買回転率は-0.89です。